1-Brom-2,3,5-tri-O-benzyl-D-arabinofuranose | 52492-40-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-Brom-2,3,5-tri-O-benzyl-D-arabinofuranose
• 英文别名: 2,3,5-tri-O-benzyl-α-D-arabinofuranosyl bromide；1-Brom-2,3,5-tri-O-benzyl-α-D-arabinofuranose；(2R,3S,4R,5R)-2-bromo-3,4-bis(phenylmethoxy)-5-(phenylmethoxymethyl)oxolane
• CAS: 52492-40-7
• 化学式: C₂₆H₂₇BrO₄
• 分子量: 483.402
• InChiKey: RNUQQVREQNIKHF-XPGKHFPBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  31
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Brom-2,3,5-tri-O-benzyl-D-arabinofuranose 在 甲醇 、 无水碳酸镉 、 碘代三甲硅烷 、 氨 作用下， 以 硝基甲烷 、 二氯甲烷 为溶剂， 反应 19.0h， 生成 2-((3S,4S,5R)-3,4-Dihydroxy-5-hydroxymethyl-tetrahydro-furan-2-yl)-9-hydroxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-2-ium; bromide
  参考文献：
  名称：

  Synthesis and antitumor activity of quaternary ellipticine glycosides, a series of novel and highly active antitumor agents

  摘要：

  A series of ellipticine glycosides [2-N-glycosyl quaternary pyridinium salts of three ellipticines: ellipticine (1), 9-methoxyellipticine (2), and 9-hydroxyellipticine (4)] were stereoselectively synthesized in good yields by an improved condensation reaction between ellipticines [1, 2, and 9-acetoxyellipticine (3)] and protected (peracylated and perbenzylated) glycosyl halides with cadmium carbonate, followed by deprotection. These glycosides were preliminarily evaluated for their antitumor activity in the L1210 leukemia system. Twenty-six (53%) of the 49 glycosides tested were curative, and five [9-hydroxyellipticine L-arabinopyranoside (41b), D-lyxofuranoside (43a), L-lyxopyranoside (44b), D-xylofuranoside (49a), and L-rhamnopyranoside (56)] were selected for extended evaluation on the basis of their high levels of activity. The structure-activity relationships are discussed. The selected glycosides showed remarkable activity in six different murine tumor systems with excellent therapeutic ratios; their efficacy surpassed that of doxorubicin against three of these systems. On the basis of these results and ease of formulation, the two glycosides 41b (SUN4599) and 49a (SUN5073) were selected for further preclinical evaluation and possible clinical development.

  DOI：

  10.1021/jm00402a007
• 作为产物：
  描述：

  1-O-acetyl-2,3,5-O-tris(phenylmethyl)-β-D-arabinofuranose 生成 1-Brom-2,3,5-tri-O-benzyl-D-arabinofuranose
  参考文献：
  名称：

  MARYANOFF, BRUCE E.;REITZ, ALLEN B.;NORTEY, SAMUEL O., TETRAHEDRON, 44,(1988) N 11, C. 3093-3106

  摘要：

  DOI：

文献信息

• Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
  申请人：——

  公开号：US20020147160A1

  公开（公告）日：2002-10-10

  The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

  本发明提供了核苷化合物及其某些衍生物，这些衍生物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，可用于治疗RNA依赖性RNA病毒感染。它们特别适用于作为丙型肝炎病毒（HCV）NS5B聚合酶的抑制剂，作为HCV复制的抑制剂，以及/或用于治疗丙型肝炎感染。本发明还描述了包含这种核苷化合物的药物组合物，单独使用或与其他对RNA依赖性RNA病毒感染，特别是HCV感染有效的制剂组合使用。还公开了使用本发明的核苷化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。
• Oligonucleotides having modified nucleoside units
  申请人：——

  公开号：US20040014957A1

  公开（公告）日：2004-01-22

  Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

  披露的是包括一个或多个修饰核苷单元的寡核苷酸和寡核苷糖。这些寡核苷酸和寡核苷糖特别适用于作为反义剂、核酶、适配体、siRNA试剂、探针和引物，或者当它们与RNA杂交时，作为包括RNase H和dsRNase的RNA切割酶的底物。
• [EN] OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS<br/>[FR] OLIGONUCLEOTIDES A UNITES NUCLEOSIDIQUES MODIFIEES
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2003099840A1

  公开（公告）日：2003-12-04

  Disclosed are oligonucleotides and oligonucleosides that include one or more modified nucleoside units. The oligonucleotides and oligonucleosides are particularly useful as antisense agents, ribozymes, aptamer, siRNA agents, probes and primers or, when hybridized to an RNA, as a substrate for RNA cleaving enzymes including RNase H and dsRNase.

  揭示了包含一个或多个修饰核苷酸单元的寡核苷酸和寡核苷苷。这些寡核苷酸和寡核苷苷特别适用作为反义物质、核酶、适配体、siRNA物质、探针和引物，或者在与RNA杂交时，作为RNA裂解酶（包括RNase H和dsRNase）的底物。
• ara-7-Desazaxanthosin — ein Xanthin-Nucleosid mit stabiler N-glycosylischer Bindung
  作者：Frank Seela、Ulrich Liman

  DOI：10.1002/jlac.198419840210

  日期：1984.2.13

  ara-7-Desazaxanthosin (2) wurde durch Phasentransferglycosylierung von 2,4-Dimethoxy-7H-pyrrolo[2,3-d]pyrimidin (5b) mit der Halogenose 6 dargestellt. Von dem bei der Glycosylierung bevorzugt gebildeten β-Anomer 8 wurden die Benzylschutzgruppen mit Bortrichlorid entfernt und die 2,4-Dimethoxyreste mit Säure abgespalten. Das 7-Desazapurin-Nucleosid 2 besitzt im Gegensatz zu Xanthosin (1a) eine bei saurer

  ARA -7- deazaxanthosine（2）的制备是通过相转移糖基化的2,4-二甲氧基- 7 ħ吡咯并[2,3- d ]嘧啶（图5b与halogenose）6。用三氯化硼除去优选在糖基化反应中形成的β-端基异构体8的苄基保护基，并用酸分离出2，4-二甲氧基。与黄嘌呤（1a）相反，7-脱氮嘌呤核苷2具有在酸水解时稳定的N-糖基键。通过比较嘌呤核苷与2的动力学参数描述了质子催化水解的反应机理，也解释了吡咯并[2,3- d ]嘧啶核苷2的稳定性。
• NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYERMASE
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20170183373A1

  公开（公告）日：2017-06-29

  The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such nucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the nucleoside compounds of the present invention.

  本发明提供了核苷类化合物及其某些衍生物，这些化合物是RNA依赖性RNA病毒聚合酶的抑制剂。这些化合物是RNA依赖性RNA病毒复制的抑制剂，对于治疗RNA依赖性RNA病毒感染非常有用。它们特别适用于作为乙型肝炎病毒（HCV）NS5B聚合酶的抑制剂，作为HCV复制的抑制剂，和/或用于治疗丙型肝炎感染。该发明还描述了含有这种核苷类化合物的药物组合物，单独使用或与其他针对RNA依赖性RNA病毒感染，特别是HCV感染的药物一起使用。还公开了使用本发明的核苷类化合物抑制RNA依赖性RNA聚合酶、抑制RNA依赖性RNA病毒复制和/或治疗RNA依赖性RNA病毒感染的方法。